Representativeness in randomised clinical trials supporting acute coronary syndrome guidelines

Current clinical practice guidelines for managing acute coronary syndrome rely on data from randomised clinical trials. However, the extent to which these trials reflect the broader patient population remains unclear. While prior research has established that RCTs form the backbone of evidence-based medicine, gaps persist regarding their demographic and geographic inclusivity. No prior work had resolved whether these trials accurately capture the diversity of ACS patients globally. This uncertainty drives the need to assess the representativeness of trial populations and their alignment with real-world care practices. The lack of comprehensive data on subgroup representation and treatment patterns in RCTs has limited the generalizability of guideline recommendations. Understanding these limitations is crucial for improving the relevance of clinical guidelines. Researchers have noted that RCTs often exclude certain demographics, such as elderly or non-white patients, which may skew the applicability of findings. Addressing these gaps could enhance the reliability of evidence used in guideline development.

This study aimed to evaluate the representativeness of patients and care practices in randomised clinical trials supporting acute coronary syndrome guidelines. The researchers sought to determine whether these trials reflect the broader ACS population and current standard of care. By analysing trial data, they aimed to identify under-represented groups and treatment patterns. The motivation stemmed from the need to ensure that guideline recommendations are based on inclusive and up-to-date evidence. The study focused on geographic and demographic diversity within trial populations. It also examined the alignment of treatment protocols with contemporary clinical practices. The goal was to highlight areas where trial data may not fully represent the real-world ACS patient experience. This work provides insights into how evidence is shaped and applied in clinical guidelines.

The researchers reviewed clinical practice guidelines for ST- and non-ST-elevation acute coronary syndrome from American and European sources. They extracted all references and recommendations from these guidelines to identify relevant randomised clinical trials. A total of 2128 references and 600 recommendations were screened. The study focused on 407 primary RCT publications supporting these guidelines. Geographic representation was assessed by examining recruitment regions across continents. Demographic data included age, gender, and race of enrolled patients. Treatment patterns such as percutaneous coronary intervention and fibrinolysis were compared with current clinical practices. Mortality rates were also evaluated to assess trial outcomes. The analysis provided a comprehensive overview of trial inclusivity and relevance.

The analysis revealed that 52.6% of RCTs recruited patients in North America and 73.2% in Europe, with other regions under-represented. Only 25.3% of trials included patients from Asia. A significant proportion of RCTs (31.4%) did not enrol any patients with acute coronary syndrome. Elderly, female, and non-white patients were notably under-represented in these trials. The incidence of reperfusion treatments in RCTs did not align with current clinical practices. For example, percutaneous coronary intervention was reported in only 42.7% of RCTs. In contrast, fibrinolysis was used 3.3 times more frequently than primary PCI for ST-Elevation Myocardial Infarction patients. All-cause mortality in these RCTs was 11.9% with follow-up ≤1 year. These findings suggest a lack of alignment between trial data and real-world patient care.

The study found that randomised clinical trials supporting acute coronary syndrome guidelines are not fully representative of the broader patient population. Geographic and demographic disparities were evident in trial recruitment. The treatment patterns observed in these trials do not reflect current clinical practices. Under-representation of certain subgroups may limit the generalizability of guideline recommendations. The researchers propose that trialists should make efforts to ensure inclusivity in future studies. While historical evidence accumulation may partially explain these gaps, current practices should aim for broader representation. The findings suggest that guideline recommendations may not fully capture the diversity of ACS patients. The authors recommend that future trials should strive to include a wider range of patient demographics and treatment approaches.